NRG Oncology has announced a broad reshaping of its scientific and operational leadership, appointing five experienced cancer researchers and clinical research professionals to senior positions across committees responsible for translational science, pharmacy, protocol support, data quality, and mentorship. The changes place specialists in biomarker development, investigational therapeutics, clinical trial infrastructure, and workforce training at the center of one of the largest cancer research networks in North America.
The appointments reflect the increasingly integrated nature of modern oncology research, in which laboratory discoveries, clinical trial design, pharmacy operations, patient safety, data management, and professional development must function as a single system. NRG Oncology is part of the National Cancer Institute’s National Clinical Trials Network and coordinates multicenter studies across more than 1,300 research sites worldwide, with a major focus on breast, gynecologic, prostate, and other localized or locally advanced cancers.
Rebecca Arend, MD, MPH, has been appointed Gynecology Oncologist Vice Chair of the NRG Translational Science Committee. A gynecologic oncologist, surgeon-scientist, and clinical trial leader, Arend studies how molecular features of cancer can be converted into more precise methods of screening, prognosis, and treatment selection. Her work includes DNA, RNA, protein, and circulating tumor DNA, or ctDNA, a form of genetic material released by tumors into the bloodstream that can provide a minimally invasive view of cancer biology.
Arend’s research is especially focused on ovarian, endometrial, cervical, and other gynecologic cancers, diseases in which tumors can vary substantially at the molecular level even when they arise in the same organ. Biomarker-driven treatment aims to identify those differences and match patients with therapies most likely to work. As Associate Director of Clinical Research at the O’Neal Comprehensive Cancer Center, Arend oversees trial infrastructure, protocol development, workforce training, and the integration of translational research into clinical programs. Within NRG, she is Translational Science Chair of the Ovarian Subcommittee under the Gynecologic Cancer Committee and is involved in developing early-career oncology investigators.
Robin Lockhorst, PharmD, BCOP, BCPS, has been appointed Chair of the NRG Pharmacy Subcommittee. With more than 15 years of experience at Avera Cancer Institute, Lockhorst has worked across oncology pharmacy, bone marrow transplantation, solid organ transplantation, hepatology, and clinical research. She currently serves as Director of Clinical Research, Oncology, where she is expanding satellite research programs and helping build early-phase trial capabilities across the Great Plains region.
Pharmacy leadership is central to the safe delivery of experimental cancer treatments. Clinical pharmacists review protocols, manage investigational drug services, verify dosing and drug interactions, and help ensure that treatment is administered according to highly specific study requirements. Lockhorst has led operational improvements in these areas while supporting protocol review and multidisciplinary education. Her work has also included mentoring pharmacy trainees and helping advance South Dakota’s drug donation and repository pilot program, an initiative designed to improve access to eligible medications.
David Miyamoto, MD, PhD, has been appointed Radiation Oncology Vice Chair of the NRG Translational Science Committee. A radiation oncologist and physician-scientist at Massachusetts General Hospital, an Associate Professor at Harvard Medical School, and an Associate Member of the Broad Institute of MIT and Harvard, Miyamoto investigates how molecular testing and advanced imaging can make cancer treatment more predictive. His laboratory research has emphasized liquid biopsies, tumor genomic analysis, and imaging technologies for prostate and bladder cancers.
The goal of this work is to identify biological signals that reveal whether a tumor is responding to treatment, developing resistance, or progressing before those changes become obvious through conventional clinical assessments. Miyamoto has led NIH-funded research involving liquid biopsy and prostate-specific membrane antigen, or PSMA, positron emission tomography imaging in patients receiving Lu-PSMA-617 radioligand therapy. This treatment delivers radiation to cancer cells that express PSMA, and biomarkers may help determine which patients are most likely to benefit. Miyamoto has also served in translational leadership roles on major multicenter studies, including NRG-GU015, ECOG-ACRIN-NRG 8185, and the PARTIQoL trial.
Elena Nelson, MBA, CCRC, has been appointed Vice Chair of the Clinical Research Associate Subcommittee within the NRG Protocol Support Committee. Nelson brings more than 15 years of oncology research experience from the University of Florida Health Cancer Center, where she serves as Data Management and Academic Research Consortium Network Manager. In that role, she leads data operations for approximately 150 trials involving solid tumors, hematologic malignancies, pediatric cancers, and early-phase therapies.
High-quality data are essential to determining whether a treatment is safe and effective. Nelson has developed standardized workflows to improve the accuracy, completeness, and timeliness of trial information, including data submitted for NCI-sponsored and experimental therapeutics studies. She is also a RECIST subject matter expert. RECIST, or Response Evaluation Criteria in Solid Tumors, is a standardized system used to measure whether tumors have shrunk, remained stable, or grown during treatment. Nelson has worked with NRG on the RECIST CLASS project and has served as both a member and mentor within the Protocol Support Committee.
Cortney Montgomery, MD, MHSc, has been appointed Vice Chair of the NRG Protocol Support Committee Mentorship Subcommittee. With more than 25 years of experience in oncology research nursing and clinical trial coordination, Montgomery has worked in academic medical centers, comprehensive cancer centers, and direct patient-care settings. At UPMC Hillman Cancer Center, she serves as a Clinical Research Coordinator and Treatment Nurse, managing patient screening, informed consent, investigational drug administration, chemotherapy delivery, and protocol compliance while helping establish a new Clinical Translational Research Center.
Montgomery has coordinated Phase I through Phase IV studies, including industry-sponsored, cooperative group, and investigator-initiated trials. Her clinical research experience spans breast cancer, gynecologic oncology, and early-phase therapeutics, where careful monitoring is particularly important because experimental treatments may involve uncertain dosing, novel mechanisms, or previously unrecognized toxicities. She has also contributed to clinical trial awareness and outreach through the Carol Glock Foundation and has served NRG as a committee member, mentor, and liaison to the Breast Cancer Committee and Uterine Corpus Cancer Subcommittee.
Together, the appointments highlight how cancer research increasingly depends on collaboration across disciplines rather than on isolated discoveries. Biomarker scientists need reliable clinical samples and high-quality datasets; radiation and medical oncologists require pharmacy systems capable of delivering complex therapies; and clinical research teams need experienced mentors to sustain the workforce behind multicenter trials. NRG Oncology said the new leaders will help advance its research while continuing the contributions of outgoing vice chairs. Current committee leadership and member openings are listed on the organization’s website.
Subject of Research: Leadership changes in a major oncology clinical trials network, with emphasis on translational cancer research, biomarkers, pharmacy operations, clinical trial data management, and research mentorship.
Article Title: NRG Oncology Appoints New Leaders to Advance Precision Cancer Research and Clinical Trials
Web References: https://www.nrgoncology.org/Current-Openings ; https://www.nrgoncology.org
References: NRG Oncology leadership announcement and organizational information provided in the source material.
Keywords: NRG Oncology, cancer research, clinical trials, translational science, biomarkers, circulating tumor DNA, liquid biopsy, radiation oncology, gynecologic oncology, pharmacy research, RECIST, precision medicine, oncology leadership, clinical research mentorship
Tags: biomarker discovery in cancercancer research leadershipcancer research mentorship programsclinical trial infrastructure developmentdata quality and management in clinical studiesinvestigational therapeutics in clinical trialsmolecular diagnostics in cancer treatmentmultidisciplinary approach to cancer researchmultidisciplinary cancer research networksNRG Oncology clinical research initiativestranslational science in oncologyworkforce training in oncology research
